CVRX vs. CLPT, QIPT, ARAY, DRTS, OBIO, TELA, DCTH, PROF, RCEL, and KRMD
Should you be buying CVRx stock or one of its competitors? The main competitors of CVRx include ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), Accuray (ARAY), Alpha Tau Medical (DRTS), Orchestra BioMed (OBIO), TELA Bio (TELA), Delcath Systems (DCTH), Profound Medical (PROF), AVITA Medical (RCEL), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry.
ClearPoint Neuro (NASDAQ:CLPT) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
ClearPoint Neuro has higher earnings, but lower revenue than CVRx. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.
ClearPoint Neuro has a net margin of -78.84% compared to ClearPoint Neuro's net margin of -123.58%. ClearPoint Neuro's return on equity of -66.05% beat CVRx's return on equity.
In the previous week, ClearPoint Neuro had 7 more articles in the media than CVRx. MarketBeat recorded 9 mentions for ClearPoint Neuro and 2 mentions for CVRx. CVRx's average media sentiment score of 0.96 beat ClearPoint Neuro's score of 0.44 indicating that ClearPoint Neuro is being referred to more favorably in the media.
ClearPoint Neuro has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, CVRx has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.
ClearPoint Neuro received 4 more outperform votes than CVRx when rated by MarketBeat users. Likewise, 86.96% of users gave ClearPoint Neuro an outperform vote while only 57.14% of users gave CVRx an outperform vote.
ClearPoint Neuro currently has a consensus price target of $12.00, indicating a potential upside of 98.35%. CVRx has a consensus price target of $16.60, indicating a potential upside of 113.92%. Given ClearPoint Neuro's higher probable upside, analysts plainly believe CVRx is more favorable than ClearPoint Neuro.
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by insiders. Comparatively, 18.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
ClearPoint Neuro beats CVRx on 10 of the 18 factors compared between the two stocks.
Get CVRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
